Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation

By sjmartinez • February 9, 2024

abatacept, acitretin, adalimumab, apremilast, biologics, brodalumab, certolizumab, cyclosporine, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, vaccination, vaccines,

Tags: abatacept, acitretin, adalimumab, apremilast, Biologics, brodalumab, certolizumab, cyclosporine, Dermatology, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, Publications, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, Vaccination, vaccines

Autoimmune Bullous Diseases: Therapeutic Update

Kasperkiewicz M, van Beek N, Schmidt E. Autoimmune Bullous Diseases: Therapeutic Update. Drugs. 2026 Feb 23. doi: 10.1007/s40265-026-02292-3. Epub ahead of print. PMID: 41729378.

Systemic Corticosteroid Exposure in Patients with Atopic Dermatitis: A US Population-Based Study

Bunick CG, Vleugels RA, Lebwohl M, Armstrong AW, Grada A, Yue EX, Saranadasa M, Wegrzyn L, D'Andrea E. Systemic Corticosteroid Exposure in Patients with Atopic[...]

Onset and depth of response with abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis, including prominent head-and-neck dermatitis: A post hoc analysis of the head-to-head phase 3 JADE DARE study

Armstrong AW, Gooderham MJ, Eyerich K, Reich K, Blauvelt A, Hong HC, Edwards RA, Bonfanti G, Clibborn C, Biswas P, Chan G, Feeney C, Güler[...]